

Alexander C Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2441791/publications.pdf>

Version: 2024-02-01

33
papers

11,493
citations

279798

23
h-index

434195

31
g-index

37
all docs

37
docs citations

37
times ranked

21637
citing authors

#	ARTICLE	IF	CITATIONS
1	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600 <i>i</i> -mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1098-1106.	7.0	32
2	Human epigenetic and transcriptional T ^A cell differentiation atlas for identifying functional T ^A cell-specific enhancers. <i>Immunity</i> , 2022, 55, 557-574.e7.	14.3	47
3	A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. <i>Nature Immunology</i> , 2022, 23, 660-670.	14.5	191
4	Signaling Through Fc γ RIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834988.	4.8	26
5	Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T ^A cell responses. <i>Cancer Cell</i> , 2022, 40, 738-753.e5.	16.8	19
6	Abstract 3579: T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade. <i>Cancer Research</i> , 2022, 82, 3579-3579.	0.9	0
7	Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 162-170.	6.3	81
8	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. <i>JAMA Internal Medicine</i> , 2021, 181, 195.	5.1	168
9	Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa120.	2.9	26
10	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. <i>Nature Communications</i> , 2021, 12, 346.	12.8	107
11	Abstract PO068: Distinct immune signatures predicting clinical response to PD-1 blockade therapy in gynecological cancers revealed by high-dimensional immune profiling. , 2021, , .		0
12	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	30.7	218
13	Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19. <i>Science Immunology</i> , 2021, 6, .	11.9	152
14	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T ^A cells. <i>Cell Reports</i> , 2021, 35, 109120.	6.4	60
15	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. <i>Nature Medicine</i> , 2021, 27, 1280-1289.	30.7	365
16	Dichotomous and stable gamma delta T-cell number and function in healthy individuals. , 2021, 9, e002274.		13
17	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. <i>JCO Oncology Practice</i> , 2021, 17, e1879-e1886.	2.9	2
18	Alpha-Fetoprotein-Producing Lung Hepatoid Adenocarcinoma with Brain Metastasis Treated with S-1. <i>Case Reports in Oncology</i> , 2021, 13, 1552-1559.	0.7	9

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2915-2926.	1.5	11
20	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. <i>Science</i> , 2020, 369, .	12.6	1,280
21	Postvaccination graft dysfunction/aplastic anemia relapse with massive clonal expansion of autologous CD8+ lymphocytes. <i>Blood Advances</i> , 2020, 4, 1378-1382.	5.2	16
22	Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. <i>Immunity</i> , 2020, 52, 825-841.e8.	14.3	497
23	TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. <i>Nature</i> , 2019, 571, 211-218.	27.8	934
24	TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 ⁺ T Cell-Fate Decision. <i>Immunity</i> , 2019, 51, 840-855.e5.	14.3	409
25	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. <i>Nature Medicine</i> , 2019, 25, 454-461.	30.7	466
26	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. <i>Nature Medicine</i> , 2018, 24, 563-571.	30.7	1,150
27	Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 73-81.	3.3	25
28	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. <i>British Journal of Cancer</i> , 2018, 119, 1200-1207.	6.4	83
29	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. <i>Nature</i> , 2018, 560, 382-386.	27.8	1,836
30	Non-conventional Inhibitory CD4 ⁺ Foxp3 ^{hi} PD-1 ^{hi} T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	16.8	112
31	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017, 545, 60-65.	27.8	1,280
32	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. <i>Cell</i> , 2016, 167, 1540-1554.e12.	28.9	830
33	Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. <i>Science</i> , 2016, 354, 1160-1165.	12.6	939